Targets › ALDH2
6 programs from 6 companies in 6 trials: 3 Phase 1, 2 Phase 2, 1 Phase 3; Oncology, Ophthalmology, Neurology; next expected readout Dec 2026.
Mitochondrial aldehyde dehydrogenase with broad substrate specificity which participates in the detoxification of ethanol-derived acetaldehyde and endogenous aldehydes, including those arising from lipid peroxidation. The reaction mechanism involves a nucleophilic attack on the aldehyde substrate, resulting in formation of a thiohemiacetal intermediate. (UniProt, P05091)
Open in Phaseline: the race on ALDH2, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| Peking Union Medical College Hospital | Edaravone Dexborneol Sublingual Tablets Free radical scavenger and neuroprotectant (Edaravone); vasodilator and cerebral blood flo | ALDH2 | Phase 3 | Cerebral Small Vessel Disease | Oct 2027 |
| Foresee Pharmaceuticals | Mirivadelgat Selective aldehyde dehydrogenase 2 (ALDH2) activator | ALDH2 | Phase 2 | Group 3 Pulmonary Hypertension | Feb 2028 |
| Memorial Sloan Kettering Cancer Center | Disulfiram Aldehyde dehydrogenase inhibitor | ALDH2 | Phase 2 | Osteosarcoma | Mar 2028 |
| Case Comprehensive Cancer Center | Disulfiram Aldehyde dehydrogenase inhibitor | ALDH2 | Phase 1 | Relapsed Sarcomas | Dec 2026 |
| University of Washington | Disulfiram Aldehyde dehydrogenase inhibitor | ALDH2 | Phase 1 | Inherited Retinal Dystrophy Primarily Involving Sensory Retina | Feb 2027 |
| University of Rochester | disulfiram Aldehyde dehydrogenase inhibitor | ALDH2 | Phase 1 | Alcohol Use Disorder | May 2029 |
Relapsed Sarcomas (1) Inherited Retinal Dystrophy Primarily Involving Sensory Retina (1) Cerebral Small Vessel Disease (1) Osteosarcoma (1) Group 3 Pulmonary Hypertension (1) Alcohol Use Disorder (1)
small molecule (6)
Case Comprehensive Cancer Center (1) University of Washington (1) Peking Union Medical College Hospital (1) Memorial Sloan Kettering Cancer Center (1) Foresee Pharmaceuticals (1) University of Rochester (1)
–
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.